In a research report published Monday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc (NASDAQ:CYTX), with a $5.00 …
All sickle cell community and investor eyes are on Mast Therapeutics (NYSEMKT:MSTX) this month, as MSTX prepares to roll out pivotal data from …
Maxim analyst Jason McCarthy weighed in with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the gene-therapy-product maker announced that a pivotal phase III study …
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares are tumbling 4% today, with sales for its generic copaxone (glatopa), an injection designed to treat patients with …
In the past week, Mast Therapeutics Inc (NYSEMKT:MSTX) stock has seen a price increase from $0.40 to $0.
Biotech firm Sophiris Bio Inc (NASDAQ:SPHS) just posted second-quarter results as well as an update on its progress for its clinical development program. …
Maxim analyst Jason McCarthy provides insight on shares of Galena Biopharma Inc (NASDAQ:GALE) after the company posted second-quarter results. While McCarthy reiterates a Buy …
Maxim analyst Jason McCarthy weighed in with a few insights on Inovio Pharmaceuticals Inc (NASDAQ:INO), after the company announced that the phase I study …
Maxim analyst Jason Kolbert offers commentary on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the biotech firm reported its second-quarter results and …
In a research note released Tuesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a $5.00 price target, …
